HUNTINGTON, N.Y., June 24,
2024 /PRNewswire/ -- Sen-Jam
Pharmaceutical is pleased to announce the successful
completion of participant enrollment for the clinical trial of its
innovative therapeutic, SJP-002C in partnership with Duke University. This milestone marks a significant
step forward in the development of an effective and affordable
treatment with the potential to reduce symptoms and tissue damage
from Upper Respiratory Infections (URIs)/COVID.
Key Highlights:
- Full Enrollment Achieved: The trial protocol called for 150
participants, and we are proud to report that this target has been
met. Initially, recruitment was slow with only 15 participants.
However, after opening two additional sites, we successfully
recruited 135 participants within five months, demonstrating
Sen-Jam's capability to mobilize resources and commitment to
advancing this crucial research.
- Safety Profile: To date, no serious side effects have been
associated with SJP-002C, putting Sen-Jam into a position to
achieve our primary endpoint of safety for this innovative
combination product.
- Mechanism of Action: SJP-002C acts as a multi-targeted
anti-inflammatory with antiviral capabilities that are effective
against various viral strains. This makes our product suitable for
a broad population seeking to reduce symptoms and prevent
respiratory infections from advancing to pneumonia and cytokine
storm.
- Patent Protection: SJP-002C is patent-protected, ensuring
exclusive rights to market this novel therapeutic globally.
- Manufacturing Plans: Our partner KVK-Tech, is currently
scheduled to submit FDA manufacturing batches by Q4-2024. Our goal
is to offer this treatment at a significantly lower cost than
existing options such as Paxlovid, making it accessible to a larger
patient population without creating a multitude of drug-drug
interactions.
- Investor Appeal: With a market opportunity valued at
$35 billion for respiratory
infections and $16 billion for COVID
therapeutics, SJP-002C is poised to capture significant market
share. Its unique combination of safety, efficacy, and
affordability positions it as a highly attractive investment
opportunity with substantial growth potential.
- Next Steps: With the anticipation of positive results, we plan
to seek FDA approval to commence Phase 3 clinical trials.
"We are thrilled to reach this important milestone in our
clinical trial for SJP-002C," said Jim
Iversen, Co-Founder and CEO of Sen-Jam Pharmaceutical.
"Our ability to rapidly enroll participants and the absence of
serious side effects are promising indicators of the potential
impact of this treatment. We are committed to advancing this
therapy to provide a safe, effective, and affordable solution for
patients worldwide."
Sen-Jam Pharmaceutical is actively seeking retail investors,
investment partners and strategic collaborations to support the
Phase 3 clinical trials and global licensing for commercialization
of SJP-002C. They also are advancing ten other novel assets with
three of them at or approaching Phase 2 clinical trial work. Their
platform aims to revolutionize the way the world treats
inflammation and the way the pharmaceutical industry treats
humanity.
About Sen-Jam Pharmaceutical: Sen-Jam Pharmaceutical is a
drug innovation company dedicated to improving societal wellbeing
by developing novel solutions for pain and inflammation. The
company's mission is to forge a new path to better health by
creating safe and efficacious therapies for some of the world's
most widespread health challenges. Sen-Jam's innovative approach
and dedication to responsible drug development position it at the
forefront of life-enhancing pharmaceutical breakthroughs.
CONTACT INFORMATION:
Sen-Jam
Pharmaceutical
Christine
Leonard
781-913-1902
379535@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sen-jam-pharmaceutical-completes-enrollment-for-phase-2-upper-respiratory-infectioncovid-therapeutic-302180360.html
SOURCE Sen-Jam Pharmaceutical